• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (72)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Prognosis/ Outcomes  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Cohort Study

Lara R. Fairall, PhD; Max O. Bachmann, PhD; Goedele M. C. Louwagie, MD; Cloete van Vuuren, MD; Perpetual Chikobvu, PhD; Dewald Steyn, MD; Gillian H. Staniland; Venessa Timmerman, MSc; Mpumelelo Msimanga, MSc; Chris J. Seebregts, PhD; Andrew Boulle, MSc; Ralph Nhiwatiwa, MD; Eric D. Bateman, MD; Merrick F. Zwarenstein, MSc; Ronald D. Chapman, MD

Arch Intern Med. 2008;168(1):86-93.

Background  The effectiveness of the South African government's expanding antiretroviral treatment program is unknown. Observational studies of treatment effectiveness are prone to selection bias, rarely compare patients receiving antiretroviral treatment with similar patients not receiving antiretroviral treatment, and underestimate mortality rates unless patients are actively followed up.

Methods  We followed up 14 267 patients in the Public Sector Anti-Retroviral Treatment project in Free State, South Africa, for up to 20 months after enrollment. A total of 3619 patients received highly active triple antiretroviral treatment (HAART) for up to 19 months (median, 6 months; interquartile range, 3-9 months) after enrollment. Patients' clinical data were linked with the national mortality register. Marginal structural regression models adjusted for baseline and time-varying covariates.

Results  Of 4570 patients followed up for at least 1 year, 53.2% died. Eighty-seven percent of patients who died had not received HAART. HAART was associated with lower mortality (hazard ratio, 0.14; 95% confidence interval [CI], 0.11-0.18) and with the presence of tuberculosis (hazard ratio, 0.61; 95% CI, 0.46-0.81) after adjusting for age, sex, weight, clinic, district, CD4 cell count, cotrimoxazole therapy, tuberculosis at baseline, and previous antiretroviral therapy. Cotrimoxazole therapy was associated with lower mortality (hazard ratio, 0.37; 95% CI, 0.32-0.42). Each month of HAART was associated with an increase in CD4 cell count of 15.1 cells/µL (95% CI, 14.7-15.5 cells/µL) and with an increase in body weight of 602 g (95% CI, 548-658 g).

Conclusions  HAART provided through these South African government health services seems as effective as that provided in high-income countries. Delays starting HAART contributed to high mortality rates. Faster expansion and timely commencement of HAART are needed.

Author Affiliations: Knowledge Translation Unit, University of Cape Town Lung Institute (Dr Fairall), Infectious Disease Epidemiology Unit, School of Public Health and Family Medicine (Dr Boulle), and Department of Medicine (Dr Bateman), University of Cape Town, and Biomedical Informatics Research Division, Medical Research Council (Mss Staniland and Timmerman, Mr Msimanga, and Dr Seebregts), Cape Town, and Department of Community Health, Faculty of Health Sciences (Drs Louwagie and Chikobvu), and Division of Infectious Diseases, Department of Internal Medicine (Drs van Vuuren, Steyn, and Nhiwatiwa), University of the Free State, and Free State Department of Health (Dr Chapman), Bloemfontein, South Africa; Health Services Research, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, England (Dr Bachmann); and Li Ka Shing Knowledge Institute, St Michaels Hospital, and Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (Dr Zwarenstein).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe
Hallett et al.
Sex. Transm. Infect. 2011;87:621-628.
ABSTRACT | FULL TEXT  

Outreach education for integration of HIV/AIDS care, antiretroviral treatment, and tuberculosis care in primary care clinics in South Africa: PALSA PLUS pragmatic cluster randomised trial
Zwarenstein et al.
BMJ 2011;342:d2022-d2022.
ABSTRACT | FULL TEXT  

Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy
Hoffmann et al.
Clinical Infectious Diseases 2009;49:1928-1935.
ABSTRACT | FULL TEXT  

Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children
Edmonds et al.
Int J Epidemiol 2009;38:1612-1621.
ABSTRACT | FULL TEXT  

Commentary: Reducing HIV-associated tuberculosis in children
Boulle and Eley
Int J Epidemiol 2009;38:1621-1623.
FULL TEXT  

Five-Year Outcomes of the China National Free Antiretroviral Treatment Program
Zhang et al.
ANN INTERN MED 2009;151:241-251.
ABSTRACT | FULL TEXT  

Another Year ... Another Top 10 List
Zuniga
Journal of the International Association of Physicians in AIDS Care (JIAPAC 2008;7:275-278.